Patrick Borgen, MD

Articles

Key Takeaways and Future Directions: Genomic Assays in Breast Cancer Treatment

May 22nd 2025

Panelists discuss how genomic assays have become essential tools in modern breast cancer treatment, preventing overtreatment by enabling customized treatment plans that determine not only whether patients need chemotherapy but also which specific agents they should receive and whether treatment should be given before or after surgery.

Leveraging Genomic Assays to Guide Treatment Decisions: Clinical Scenarios and Expert Perspectives

May 22nd 2025

Panelists discuss how genomic testing informs real clinical scenarios, demonstrating that for a 64-year-old healthy woman with a single positive lymph node, the 21-gene assay would guide treatment decisions, with cardiac assessment influencing whether anthracycline-based chemotherapy would be used if her score was high.

Leveraging TAILORx Findings to Guide Testing and Treatment Decisions in Node-Negative Breast Cancer

May 15th 2025

Panelists discuss how the TAILORx trial data were transformative for estrogen receptor–positive breast cancer by establishing clearer thresholds for chemotherapy benefit, while raising important questions about whether younger patients with intermediate scores benefit from chemotherapy itself or from the ovarian suppression it causes.

Using RxPONDER Findings to Inform Testing and Treatment Approaches in Node-Positive Breast Cancer

May 15th 2025

Panelists discuss how the RxPONDER trial data transformed breast cancer treatment by demonstrating that postmenopausal women with 1 to 3 positive lymph nodes and low recurrence scores could safely avoid chemotherapy, while highlighting the controversy about chemotherapy benefit in premenopausal patients where clinical judgment and nuanced assessment of menopausal status remain crucial.

Utilizing the RSClin Tool to Inform Breast Cancer Treatment Decisions in the Practice Setting

May 8th 2025

Panelists discuss how the RSClin tool provides more personalized information by combining recurrence scores with clinicopathological data, offering patients specific predictions about their prognosis and potential chemotherapy benefit rather than general outcomes for patients with similar scores.

Expert Insights on Genomic Test Selection in Breast Cancer: Strategies for Node-Negative vs Node-Positive Disease

May 8th 2025

Panelists discuss how clinical factors such as nodal status influence genomic testing decisions, referencing the TAILORx and RxPONDER trials whose data demonstrated that chemotherapy benefit varies based on recurrence score and menopausal status, highlighting the need for nuanced shared decision-making rather than strict cutoffs.

Genomic Assays in Breast Cancer: Key Differences, Clinical Utility, and Test Selection

May 1st 2025

Panelists discuss how they primarily use the 21-gene assay (Oncotype DX) for estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancers with minimal nodal disease due to its robust data from multiple trials, whereas other assays such as the Breast Cancer Index (BCI) are better for evaluating extended endocrine therapy benefits.

Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners

May 1st 2025

Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.

Genomic Testing in Early-Stage Breast Cancer: Institutional and Multidisciplinary Perspectives

April 24th 2025

Discover essential insights on breast cancer awareness, prevention, and treatment options to empower your health journey.

Genomic Testing in Breast Cancer: A Predictive and Prognostic Tool in an Evolving Landscape

April 24th 2025

Discover essential insights on breast cancer awareness, prevention, and treatment options to empower your health journey.

Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer

March 22nd 2024

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Dr. Borgen on the Importance of Addressing Opioid Use in Breast Cancer Care

March 5th 2023

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

Dr. Borgen on Treatment Strategies for Male Breast Cancer

March 9th 2021

Patrick Borgen, MD, discusses treatment strategies for patients with male breast cancer.

Dr. Borgen on Removing Opioids from Surgical Oncology

December 18th 2018

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses a plan to remove opioids from surgical oncology and the treatment of breast cancer.

Dr. Borgen on Precision Medicine in Breast Cancer

November 20th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

Dr. Borgen on Deciding Factors of Lymph Node Dissection in Breast Cancer

August 23rd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses important factors of deciding which patients with breast cancer need axillary lymph node dissection.

Dr. Borgen Discusses HER2 Blockade in Breast Cancer

February 22nd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Dr. Borgen Discusses Trials in Neoadjuvant HER2+ Breast Cancer

January 16th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses clinical trials in neoadjuvant HER2 breast cancer.

Dr. Borgen on Advancements With HER2+ Breast Cancer

November 17th 2017

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.